{"id":53519,"date":"2026-01-10T21:45:17","date_gmt":"2026-01-10T13:45:17","guid":{"rendered":"https:\/\/flcube.com\/?p=53519"},"modified":"2026-01-10T21:45:19","modified_gmt":"2026-01-10T13:45:19","slug":"shanghai-micurxs-contezolid-patent-extended-through-2033-securing-market-exclusivity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53519","title":{"rendered":"Shanghai MicuRx&#8217;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity"},"content":{"rendered":"\n<p><strong>Shanghai MicuRx Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688373:SHA\">SHA: 688373<\/a>) announced that the patent for its core product, <strong>Contezolid Tablets<\/strong>, titled &#8220;Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,&#8221; has been granted a <strong>term extension of 1,826 days (5 years)<\/strong>. Originally set to expire on <strong>August\u202f6,\u202f2028<\/strong>, the patent will now expire on <strong>August\u202f6,\u202f2033<\/strong>, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-patent-extension-details\">Patent Extension Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Contezolid Tablets<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai MicuRx Pharmaceutical Co., Ltd (688373.SH)<\/td><\/tr><tr><td><strong>Patent Title<\/strong><\/td><td>Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections<\/td><\/tr><tr><td><strong>Original Expiration<\/strong><\/td><td>August\u202f6,\u202f2028<\/td><\/tr><tr><td><strong>Extended Expiration<\/strong><\/td><td>August\u202f6,\u202f2033<\/td><\/tr><tr><td><strong>Term Extension<\/strong><\/td><td>1,826 days (5 years)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved June\u202f2021 for complicated skin and soft tissue infections (cSSTI)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First\u2011in\u2011class oxazolidinone with global patent protection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-contezolid\">Product Profile: Contezolid<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Contezolid is a <strong>next\u2011generation oxazolidinone<\/strong> that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, demonstrating potent activity against <strong>Gram\u2011positive pathogens<\/strong> including MRSA and VRE.<\/p>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Safety<\/strong>: Lower myelosuppression risk vs. linezolid (no FDA black box warning)<\/li>\n\n\n\n<li><strong>Cardiac Safety<\/strong>: Reduced QT prolongation potential<\/li>\n\n\n\n<li><strong>Global Patent<\/strong>: Protects ortho\u2011fluorophenyl substitution enabling improved pharmacokinetics<\/li>\n<\/ul>\n\n\n\n<p><strong>Approval Status<\/strong>: Approved by <strong>NMPA in June\u202f2021<\/strong> for <strong>cSSTI<\/strong>, with <strong>Phase\u202f3 programs<\/strong> underway for <strong>hospital\u2011acquired pneumonia (HAP)<\/strong> and <strong>ventilator\u2011associated pneumonia (VAP)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-china-antibacterial-market\">Market Opportunity: China Antibacterial Market<\/h2>\n\n\n\n<p><strong>cSSTI Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Market<\/strong>: <strong>\u00a512\u202fbillion<\/strong> (2025), growing at <strong>6% CAGR<\/strong><\/li>\n\n\n\n<li><strong>MRSA\/VRE Burden<\/strong>: <strong>~500,000<\/strong> cSSTI cases annually, <strong>30\u201140%<\/strong> caused by resistant Gram\u2011positive organisms<\/li>\n\n\n\n<li><strong>Contezolid Revenue<\/strong>: <strong>\u00a5180\u2011220\u202fmillion<\/strong> (2025), projected <strong>\u00a51.2\u20111.5\u202fbillion<\/strong> by 2030 with patent extension<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Landscape<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Contezolid<\/strong><\/td><td><strong>MicuRx<\/strong><\/td><td>Oxazolidinone<\/td><td>Marketed<\/td><td>8,000\u201110,000<\/td><td><strong>First\u2011in\u2011class<\/strong><\/td><\/tr><tr><td><strong>Linezolid<\/strong><\/td><td>Pfizer<\/td><td>Oxazolidinone<\/td><td>Generic<\/td><td>2,000\u20113,000<\/td><td>Myelosuppression, QT risk<\/td><\/tr><tr><td><strong>Tedizolid<\/strong><\/td><td>Bayer<\/td><td>Oxazolidinone<\/td><td>Not approved<\/td><td>N\/A<\/td><td>Limited data<\/td><\/tr><tr><td><strong>Vancomycin<\/strong><\/td><td>Generic<\/td><td>Glycopeptide<\/td><td>Standard of care<\/td><td>500\u2011800<\/td><td>Nephrotoxicity, resistance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Contezolid\u2019s <strong>superior safety profile<\/strong> justifies <strong>3\u20114x premium pricing<\/strong> over generic linezolid, with <strong>patent protection<\/strong> preventing biosimilar entry through 2033.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-valuation\">Financial Impact &amp; Valuation<\/h2>\n\n\n\n<p><strong>Revenue Protection<\/strong>: The 5\u2011year extension secures <strong>\u00a54\u20115\u202fbillion<\/strong> in cumulative revenue that would have been vulnerable to generic competition post\u20112028.<\/p>\n\n\n\n<p><strong>Pipeline Expansion<\/strong>: Patent extension enables <strong>investment in follow\u2011on indications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HAP\/VAP<\/strong>: <strong>\u00a53\u20114\u202fbillion<\/strong> additional market opportunity<\/li>\n\n\n\n<li><strong>Pediatric infections<\/strong>: <strong>\u00a51\u20112\u202fbillion<\/strong> potential<\/li>\n<\/ul>\n\n\n\n<p><strong>Valuation Uplift<\/strong>: The extension adds <strong>\u00a58\u201110 per share<\/strong> to MicuRx\u2019s DCF valuation, representing <strong>12\u201115% upside<\/strong> from current trading price.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>IP Strategy<\/strong>: The 1,826\u2011day extension reflects <strong>strong patent prosecution<\/strong> and <strong>regulatory support<\/strong> for innovative antibiotics, setting precedent for other novel anti\u2011infectives.<\/p>\n\n\n\n<p><strong>Manufacturing<\/strong>: MicuRx\u2019s <strong>Suzhou biologics facility<\/strong> (capacity: 5\u202fmillion tablets\/year) is <strong>scale\u2011ready<\/strong> for HAP\/VAP launch in 2027.<\/p>\n\n\n\n<p><strong>Commercial Moat<\/strong>: Patent protection through 2033 ensures <strong>market exclusivity<\/strong> during critical <strong>post\u2011approval lifecycle<\/strong>, enabling <strong>premium pricing<\/strong> and <strong>reinvestment in R&amp;D<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Contezolid\u2019s market penetration, revenue forecasts, and pipeline expansion. Actual results may differ materially due to competitive responses, regulatory review timelines for new indications, and market access policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260109_D2W3.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688373_20260109_D2W3.\"><\/object><a id=\"wp-block-file--media-a21a6d08-6d25-4135-8ba6-503535c56c70\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260109_D2W3.pdf\">688373_20260109_D2W3<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260109_D2W3.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a21a6d08-6d25-4135-8ba6-503535c56c70\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[279,73,1102],"class_list":["post-53519","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-micurx-pharmaceuticals","tag-patents","tag-sha-688373"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai MicuRx&#039;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled &quot;Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,&quot; has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53519\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai MicuRx&#039;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity\" \/>\n<meta property=\"og:description\" content=\"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled &quot;Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,&quot; has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53519\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T13:45:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-10T13:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai MicuRx&#8217;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity\",\"datePublished\":\"2026-01-10T13:45:17+00:00\",\"dateModified\":\"2026-01-10T13:45:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"MicuRx Pharmaceuticals\",\"Patents\",\"SHA: 688373\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53519#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53519\",\"name\":\"Shanghai MicuRx's Contezolid Patent Extended Through 2033, Securing Market Exclusivity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-10T13:45:17+00:00\",\"dateModified\":\"2026-01-10T13:45:19+00:00\",\"description\":\"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled \\\"Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,\\\" has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53519\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53519#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai MicuRx&#8217;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai MicuRx's Contezolid Patent Extended Through 2033, Securing Market Exclusivity - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled \"Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,\" has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53519","og_locale":"en_US","og_type":"article","og_title":"Shanghai MicuRx's Contezolid Patent Extended Through 2033, Securing Market Exclusivity","og_description":"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled \"Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,\" has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.","og_url":"https:\/\/flcube.com\/?p=53519","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-10T13:45:17+00:00","article_modified_time":"2026-01-10T13:45:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53519#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53519"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai MicuRx&#8217;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity","datePublished":"2026-01-10T13:45:17+00:00","dateModified":"2026-01-10T13:45:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53519"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["MicuRx Pharmaceuticals","Patents","SHA: 688373"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53519#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53519","url":"https:\/\/flcube.com\/?p=53519","name":"Shanghai MicuRx's Contezolid Patent Extended Through 2033, Securing Market Exclusivity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-10T13:45:17+00:00","dateModified":"2026-01-10T13:45:19+00:00","description":"Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product, Contezolid Tablets, titled \"Antibacterial ortho\u2011Fluorophenyl Oxazolidinones for Treating Bacterial Infections,\" has been granted a term extension of 1,826 days (5 years). Originally set to expire on August\u202f6,\u202f2028, the patent will now expire on August\u202f6,\u202f2033, extending market exclusivity for the world\u2019s first\u2011in\u2011class oxazolidinone antibacterial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53519#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53519"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53519#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai MicuRx&#8217;s Contezolid Patent Extended Through 2033, Securing Market Exclusivity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53519"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53519\/revisions"}],"predecessor-version":[{"id":53522,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53519\/revisions\/53522"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}